Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds

Neurobiology of Disease

Volumn 37, Issue 1, 2010, Pages 38-47

  Alavijeh, Mohammad S ^a   Palmer, Alan M ^b  

^a Pharmidex   (United Kingdom)

^b MS Therapeutics Ltd   (United Kingdom)

Author keywords

CNS disorder; DMPK; Drug efficacy; Drug safety; Microdialysis; Pharmacodynamics; Pharmacokinetics; Receptor occupancy

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACTEOSIDE; BUSPIRONE; CARBAMAZEPINE; CEFAZOLIN; CENTRAL NERVOUS SYSTEM AGENTS; CISPLATIN; DIPRENORPHINE; DISUFENTON SODIUM; DOXEPIN; EMONAPRIDE; ETIRACETAM; FLUMAZENIL; GAVESTINEL; GEMCITABINE; ISOREMOXIPRIDE; LAMOTRIGINE; LEVOMEPROMAZINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; OXCARBAZEPINE; OXYCODONE; PEFLOXACIN; PHENYTOIN; PRAZOSIN; RACLOPRIDE; ROPIVACAINE; SENKTIDE; UNINDEXED DRUG; VIGABATRIN;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; INTERSTITIAL FLUID; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STROKE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; CEREBROSPINAL FLUID; EXTRACELLULAR FLUID; HUMANS; MICRODIALYSIS;

EID: 70449595570     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.09.025     Document Type: Review

References (150)

1. Ahmad R., Hirani E., Grasby P.M., and Hume S.P. Effect of reduction in endogenous dopamine on extrastriatal binding of [11C]FLB 457 in rat brain-an ex vivo study. Synapse 59 3 (2006) 162-172
2. Alavijeh M.S., and Palmer A.M. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. IDrugs 7 8 (2004) 755-763
3. Alavijeh M.S., and Patsalos P.N. A freely behaving animal model for the chronic and simultaneous study of pharmacokinetics and neuropharmacokinetics of drugs: an evaluation of carbamazepine (CBZ). Acta Neurol. Scand. 82 (1990) S50
4. Alavijeh M.S., Chishty M., Qaiser M.Z., and Palmer A.M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2 4 (2005) 554-571
5. Alfinito P.D., Huselton C., Chen X., and Deecher D.C. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res. 1098 1 (2006) 71-78
6. Alonso M.J., Bruelisauer A., Misslin P., and Lemaire M. Microdialysis sampling to determine the pharmacokinetics of unbound SDZ ICM 567 in blood and brain in awake, freely-moving rats. Pharm. Res. 12 2 (1995) 291-294
7. Andree B., Halldin C., Thorberg S.O., Sandell J., and Farde L. Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development. Nucl. Med. Biol. 27 5 (2000) 515-521
8. Aoyama T., Kotaki H., Sawada Y., and Iga T. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacology (Berl) 127 2 (1996) 117-122
9. Apparaju S.K., Gudelsky G.A., and Desai P.B. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. Cancer Chemother. Pharmacol. 61 2 (2008) 223-229
10. Assie M.B., Consul-Denjean N., Koek W., and Newman-Tancredi A. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology 75 2 (2005) 63-68
11. Assie M.B., Bardin L., Auclair A., Consul-Denjean N., Sautel F., Depoortere R., et al. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. Naunyn Schmiedebergs Arch. Pharmacol. 375 4 (2007) 241-250
12. Atack J.R., Alder L., Cook S.M., Smith A.J., and McKernan R.M. In vivo labelling of alpha5 subunit-containing GABA(A) receptors using the selective radioligand [(3)H]L-655,708. Neuropharmacology 49 2 (2005) 220-229
13. Au-Yeung S.C., Riggs K.W., Gruber N., and Rurak D.W. The use of microdialysis for the study of drug kinetics: central nervous system pharmacokinetics of diphenhydramine in fetal, newborn, and adult sheep. Drug Metab. Dispos. 35 8 (2007) 1285-1291
14. Bardin L., Assie M.B., Pelissou M., Royer-Urios I., Newman-Tancredi A., Ribet J.P., et al. Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)- am ino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters. J. Pharmacol. Exp. Ther. 312 3 (2005) 1034-1042
15. Bendels S., Kansy M., Wagner B., and Huwyler J. In silico prediction of brain and CSF permeation of small molecules using PLS regression models. Eur. J. Med. Chem. 43 8 (2008) 1581-1592
16. Bengtsson J., Ederoth P., Ley D., Hansson S., mer-Wahlin I., Hellstrom-Westas L., et al. The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. Br. J. Pharmacol. 157 6 (2009) 1085-1096
17. Benturquia N., Parrot S., Sauvinet V., Renaud B., and Denoroy L. Simultaneous determination of vigabatrin and amino acid neurotransmitters in brain microdialysates by capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 806 2 (2004) 237-244
18. Bickerdike M.J., Thomas G.B., Batchelor D.C., Sirimanne E.S., Leong W., Lin H., et al. NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J. Neurol. Sci. 278 1-2 (2009) 85-90
19. Blakeley J.O., Olson J., Grossman S.A., He X., Weingart J., and Supko J.G. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J. Neurooncol. 91 1 (2009) 51-58
20. Borg N., and Stahle L. Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2′,3′-dideoxycytidine) and BEA005 (2′, 3′-dideoxy-3′-hydroxymethylcytidine) in rats, studied by microdialysis. Antimicrob. Agents Chemother. 42 9 (1998) 2174-2177
21. Bostrom E., Simonsson U.S., and Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab. Dispos. 34 9 (2006) 1624-1631
22. Bouer R., Saivin S., Malmary M.F., Hermann P., Poey J., and Houin G. Blood and cerebral concentrations of the new potential analgesic UP 26-91 measured in vivo by microdialysis after toxic doses. Arzneimittelforschung 48 7 (1998) 745-749
23. Bouw M.R., Xie R., Tunblad K., and Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/pharmacodynamic modelling. Br. J. Pharmacol. 134 8 (2001) 1796-1804
24. Bundgaard C., Larsen F., Jorgensen M., and Gabrielsson J. Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. Eur. J. Pharm. Sci. 29 5 (2006) 394-404
25. Bundgaard C., Jorgensen M., and Larsen F. Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. Biopharm. Drug Dispos. 28 7 (2007) 349-360
26. Bundgaard C., Jorgensen M., and Mork A. An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. J. Pharmacol. Toxicol. Methods 55 2 (2007) 214-223
27. Burns H.D., Van L.K., Sanabria-Bohorquez S., Hamill T.G., Bormans G., Eng W.S., et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. U.S.A. 104 23 (2007) 9800-9805
28. Bush M.A., and Pollack G.M. Pharmacokinetics and pharmacodynamics of 7-nitroindazole, a selective nitric oxide synthase inhibitor, in the rat hippocampus. Pharm. Res. 18 11 (2001) 1607-1612
29. Catafau A.M., Suarez M., Bullich S., Llop J., Nucci G., Gunn R.N., et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage 46 2 (2009) 447-458
30. Chang Y.L., Tsai P.L., Chou Y.C., Tien J.H., and Tsai T.H. Simultaneous determination of nicotine and its metabolite, cotinine, in rat blood and brain tissue using microdialysis coupled with liquid chromatography: pharmacokinetic application. J. Chromatogr. A 1088 1-2 (2005) 152-157
31. Chaurasia C.S., Muller M., Bashaw E.D., Benfeldt E., Bolinder J., Bullock R., et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm. Res. 24 5 (2007) 1014-1025
32. Chenel M., Marchand S., Dupuis A., Lamarche I., Paquereau J., Pariat C., et al. Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. Br. J. Pharmacol. 142 2 (2004) 323-330
33. Clement R., Malinovsky J.M., Le C.P., Dollo G., Chevanne F., and Le V.R. Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. J. Pharmacol. Exp. Ther. 289 2 (1999) 1015-1021
34. Clinckers R., Smolders I., Michotte Y., Ebinger G., Danhof M., Voskuyl R.A., et al. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. Br. J. Pharmacol. 155 7 (2008) 1127-1138
35. Cosenza M., Gifford A.N., Gatley S.J., Pyatt B., Liu Q., Makriyannis A., et al. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 38 4 (2000) 477-482
36. Cremers T.I., de Vries M.G., Huinink K.D., van Loon J.P., Hart M., Ebert B., et al. Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. J. Neurosci. Methods 178 2 (2009) 249-254
37. Crespo J.A., Sturm K., Saria A., and Zernig G. Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. Psychopharmacology (Berl) 183 2 (2005) 201-209
38. Crick E.W., Osorio I., Bhavaraju N.C., Linz T.H., and Lunte C.E. An investigation into the pharmacokinetics of 3-mercaptopropionic acid and development of a steady-state chemical seizure model using in vivo microdialysis and electrophysiological monitoring. Epilepsy Res. 74 2-3 (2007) 116-125
39. Cutler L., Howes C., Deeks N.J., Buck T.L., and Jeffrey P. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J. Pharm. Sci. 95 9 (2006) 1944-1953
40. Dawson D.A., Wadsworth G., and Palmer A.M. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res. 892 2 (2001) 344-350
41. de Lange E.C., de Boer B.A., and Breimer D.D. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv. Drug Deliv. Rev. 36 2-3 (1999) 211-227
42. de Lange E.C., Ravenstijn P.G., Groenendaal D., and van Steeg T.J. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J. 7 3 (2005) E532-E543
43. Destache C.J., Pakiz C.B., Larsen C., Owens H., and Dash A.K. Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. J. Antimicrob. Chemother. 47 5 (2001) 611-615
44. Dhawan J., Deng H., Gatley S.J., Makriyannis A., Akinfeleye T., Bruneus M., et al. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse 60 2 (2006) 93-101
45. Doheny M.H., Nagaki S., and Patsalos P.N. A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug. Naunyn Schmiedebergs Arch. Pharmacol. 354 2 (1996) 157-163
46. Duffy R.A., Varty G.B., Morgan C.A., and Lachowicz J.E. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J. Pharmacol. Exp. Ther. 301 2 (2002) 536-542
47. Feng J., Li F., Zhao Y., Feng Y., and Abe Y. Brain pharmacokinetics of tetramethylpyrazine after intranasal and intravenous administration in awake rats. Int. J. Pharm. 375 1-2 (2009) 55-60
48. Finnema S.J., Halldin C., Bang-Andersen B., Gulyas B., Bundgaard C., Wikstrom H.V., et al. Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain-a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse 63 5 (2009) 378-389
49. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav. Brain Res. 73 1-2 (1996) 337-353
50. Fox E., Bungay P.M., Bacher J., McCully C.L., Dedrick R.L., and Balis F.M. Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J. Pharmacol. Exp. Ther. 301 3 (2002) 1003-1011
51. Gerrits M.A., Wiegant V.M., and Van Ree J.M. Endogenous opioids implicated in the dynamics of experimental drug addiction: an in vivo autoradiographic analysis. Neuroscience 89 4 (1999) 1219-1227
52. Graumlich J.F., McLaughlin R.G., Birkhahn D., Shah N., Burk A., Jobe P.C., et al. Subcutaneous microdialysis in rats correlates with carbamazepine concentrations in plasma and brain. Epilepsy Res. 40 1 (2000) 25-32
53. Green A.R., Ashwood T., Odergren T., and Jackson D.M. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol. Ther. 100 3 (2003) 195-214
54. Groenendaal D., Blom-Roosemalen M.C., Danhof M., and Lange E.C. High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/pharmacodynamic studies in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 822 1-2 (2005) 230-237
55. Groenendaal D., Freijer J., de M.D., Bouw M.R., Danhof M., and de Lange E.C. Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. Br. J. Pharmacol. 151 5 (2007) 701-712
56. Groenendaal D., Freijer J., de M.D., Bouw M.R., Danhof M., and de Lange E.C. Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. Br. J. Pharmacol. 151 5 (2007) 713-720
57. Heinzen E.L., and Pollack G.M. Pharmacokinetics and pharmacodynamics of l-arginine in rats: a model of stimulated neuronal nitric oxide synthesis. Brain Res. 989 1 (2003) 67-75
58. Helmy A., Carpenter K.L., and Hutchinson P.J. Microdialysis in the human brain and its potential role in the development and clinical assessment of drugs. Curr. Med. Chem. 14 14 (2007) 1525-1537
59. Hirst W.D., Stean T.O., Rogers D.C., Sunter D., Pugh P., Moss S.F., et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 553 1-3 (2006) 109-119
60. Hocht C., Opezzo J.A., and Taira C.A. Microdialysis in drug discovery. Curr. Drug. Discov. Technol. 1 4 (2004) 269-285
61. Hosoi R., Kobayashi K., Watanabe Y., and Inoue O. Discrepancy of benzodiazepine receptor occupancy between 3H-flumazenil and 125I-iomazenil in intact mouse brain. J. Neural. Transm. 106 3-4 (1999) 243-256
62. Huang H., Zhang Y., Yang R., and Tang X. Determination of baicalin in rat cerebrospinal fluid and blood using microdialysis coupled with ultra-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 874 1-2 (2008) 77-83
63. Hume S., Hirani E., Opacka-Juffry J., Myers R., Townsend C., Pike V., et al. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. Synapse 41 2 (2001) 150-159
64. Ishikawa M., Sakata M., Ishii K., Kimura Y., Oda K., Toyohara J., et al. High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int. J. Neuropsychopharmacol. (2009) 1-5
65. Jagoda E.M., Lang L., Tokugawa J., Simmons A., Ma Y., Contoreggi C., et al. Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT. Synapse 59 6 (2006) 330-341
66. Juan Y.P., and Tsai T.H. Measurement and pharmacokinetics of vincamine in rat blood and brain using microdialysis. J. Chromatogr. A 1088 1-2 (2005) 146-151
67. Kaddoumi A., Nakashima M.N., Maki T., Matsumura Y., Nakamura J., and Nakashima K. Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 791 1-2 (2003) 291-303
68. Kankaanpaa A., Ellermaa S., Meririnne E., Hirsjarvi P., and Seppala T. Acute neurochemical and behavioral effects of stereoisomers of 4-methylaminorex in relation to brain drug concentrations. J. Pharmacol. Exp. Ther. 300 2 (2002) 450-459
69. Kau Y.C., Wong K.M., Shyr M.H., Lee Y.H., and Tsai T.H. Simultaneous determination of unbound ropivacaine in rat blood and brain using microdialysis. J. Chromatogr. B Biomed. Sci. Appl. 760 1 (2001) 107-112
70. Kielbasa W., Kalvass J.C., and Stratford R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab. Dispos. 37 1 (2009) 137-142
71. Knauer C.S., Campbell J.E., Galvan B., Bowman C., Osgood S., Buist S., et al. Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy. Eur. J. Pharmacol. 591 1-3 (2008) 136-141
72. Kornhuber J., Weigmann H., Rohrich J., Wiltfang J., Bleich S., Meineke I., et al. Region specific distribution of levomepromazine in the human brain. J. Neural. Transm. 113 3 (2006) 387-397
73. Kou Y., Liu Y., Xue M., Xu Y., Liu H., Ruan J., et al. Comparative pharmacokinetics and distribution kinetics in brain of phencynonate enantiomers in rats. Int. J. Pharm. 353 1-2 (2008) 88-94
74. Kumar J.S., Prabhakaran J., Erlandsson K., Majo V.J., Simpson N.R., Pratap M., et al. Synthesis and in vivo evaluation of [O-methyl-11C](2R,4R)-4-hydroxy-2-[2-[2-[2-(3-methoxy)phenyl]ethyl]pheno xy ]ethyl-1-methylpyrrolidine as a 5-HT2A receptor PET ligand. Nucl. Med. Biol. 33 4 (2006) 565-574
75. Kurata N., Inagaki M., Iwase M., Nishimura Y., Kiuchi Y., Yamazaki Y., et al. Pharmacokinetic study of trimethadione and its metabolite in blood, liver and brain by microdialysis in conscious, unrestrained rats. Res. Commun. Mol. Pathol. Pharmacol. 89 1 (1995) 45-56
76. Langlois X., te R.P., Wintmolders C., Leysen J.E., and Jurzak M. Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. J. Pharmacol. Exp. Ther. 299 2 (2001) 712-717
77. Li J., Fish R.L., Cook S.M., Tattersall F.D., and Atack J.R. Comparison of in vivo and ex vivo [3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors. Neuropharmacology 51 1 (2006) 168-172
78. Lin J.H. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr. Drug Metab. 9 1 (2008) 46-59
79. Lingford-Hughes A.R., Wilson S.J., Cunningham V.J., Feeney A., Stevenson B., Brooks D.J., et al. GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. Psychopharmacology (Berl) 180 4 (2005) 595-606
80. Liu X., Vilenski O., Kwan J., Apparsundaram S., and Weikert R. Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab. Dispos. 37 7 (2009) 1548-1556
81. Loscher W., and Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76 1 (2005) 22-76
82. Maier D.L., Sobotka-Briner C., Ding M., Powell M.E., Jiang Q., Hill G., et al. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy. J. Pharmacol. Exp. Ther. 330 1 (2009) 342-351
83. Marchand S., Chenel M., Lamarche I., Pariat C., and Couet W. Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. J. Pharm. Sci. 92 12 (2003) 2458-2465
84. Maruyama S., Tsukada H., Nishiyama S., Kakiuchi T., Fukumoto D., Oku N., et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J. Pharmacol. Exp. Ther. 325 3 (2008) 774-781
85. Matos F.F., Rollema H., and Basbaum A.I. Simultaneous measurement of extracellular morphine and serotonin in brain tissue and CSF by microdialysis in awake rats. J. Neurochem. 58 5 (1992) 1773-1781
86. Melega W.P., Williams A.E., Schmitz D.A., DiStefano E.W., and Cho A.K. Pharmacokinetic and pharmacodynamic analysis of the actions of d-amphetamine and d-methamphetamine on the dopamine terminal. J. Pharmacol. Exp. Ther. 274 1 (1995) 90-96
87. Melega W.P., Cho A.K., Schmitz D., Kuczenski R., and Segal D.S. l-Methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J. Pharmacol. Exp. Ther. 288 2 (1999) 752-758
88. Miller T.R., Milicic I., Bauch J., Du J., Surber B., Browman K.E., et al. Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br. J. Pharmacol. 157 1 (2009) 139-149
89. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., and Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25 4 (2001) 476-488
90. Nakashima M., Shibata S., Tokunaga Y., Fujita H., Anda T., Arizono K., et al. In-vivo microdialysis study of the distribution of cisplatin into brain tumour tissue after intracarotid infusion in rats with 9L malignant glioma. J. Pharm. Pharmacol. 49 8 (1997) 777-780
91. Need A.B., McKinzie J.H., Mitch C.H., Statnick M.A., and Phebus L.A. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci. 81 17-18 (2007) 1389-1396
92. Othman A.A., Newman A.H., and Eddington N.D. The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. J. Pharm. Sci. 97 12 (2008) 5453-5470
93. Otsuka T., Ito H., Halldin C., Takahashi H., Takano H., Arakawa R., et al. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain. J. Nucl. Med. 50 5 (2009) 703-710
94. Palmer A.M., Hutson P.H., Lowe S.L., and Bowen D.M. Extracellular concentrations of aspartate and glutamate in rat neostriatum following chemical stimulation of frontal cortex. Exp. Brain Res. 75 3 (1989) 659-663
95. Palvimaki E.P., Kuoppamaki M., Syvalahti E., and Hietala J. Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT(2C) receptor occupancy in rat brain. Int. J. Neuropsychopharmacol. 2 2 (1999) 95-99
96. Pangalos M.N., Schechter L.E., and Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6 7 (2007) 521-532
97. Patel S., Fernandez-Garcia E., Hutson P.H., and Patel S. An in vivo binding assay to determine central alpha(1)-adrenoceptor occupancy using [(3)H]prazosin. Brain Res. Brain Res. Protoc. 8 3 (2001) 191-198
98. Patsalos P.N., Abed W.T., Alavijeh M.S., and O'Connell M.T. The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex. Br. J. Pharmacol. 115 3 (1995) 503-509
99. Pierson M.E., Andersson J., Nyberg S., McCarthy D.J., Finnema S.J., Varnas K., et al. [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 41 3 (2008) 1075-1085
100. Qu Y., Aluisio L., Lord B., Boggs J., Hoey K., Mazur C., et al. Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: increasing extracellular serotonin level in the frontal cortex. Pharmacol. Biochem. Behav. 92 3 (2009) 469-473
101. Rabiner E.A., Wilkins M.R., Turkheimer F., Gunn R.N., Udo de H.J., de V.M., et al. 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]- 1, 2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2- py ridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J. Pharmacol. Exp. Ther. 301 3 (2002) 1144-1150
102. Rabiner E.A., Slifstein M., Nobrega J., Plisson C., Huiban M., Raymond R., et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63 9 (2009) 782-793
103. Raje S., Cornish J., Newman A.H., Cao J., Katz J.L., and Eddington N.D. Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling. Pharm. Res. 22 4 (2005) 603-612
104. Raje S., Cornish J., Newman A.H., Cao J., Katz J.L., and Eddington N.D. Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. Biopharm. Drug Dispos. 27 5 (2006) 229-240
105. Raybon J.J., and Boje K.M. Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyric acid during tolerance in rats: effects on extracellular dopamine. J. Pharmacol. Exp. Ther. 320 3 (2007) 1252-1260
106. Roberts C., Watson J., Price G.W., and Middlemiss D.N. SB-236057-A: a selective 5-HT1B receptor inverse agonist. CNS Drug Rev. 7 4 (2001) 433-444
107. Routledge C., Gurling J., Wright I.K., and Dourish C.T. Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study. Eur. J. Pharmacol. 239 1-3 (1993) 195-202
108. Sawchuk R.J., and Elmquist W.F. Microdialysis in the study of drug transporters in the CNS. Adv. Drug Deliv. Rev. 45 2-3 (2000) 295-307
109. Scherfler C., Scholz S.W., Donnemiller E., Decristoforo C., Oberladstatter M., Stefanova N., et al. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. Neuroimage 24 3 (2005) 822-831
110. Scott-Stevens P., Atack J.R., Sohal B., and Worboys P. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. Biopharm. Drug Dispos. 26 1 (2005) 13-20
111. Senda M., Kubo N., Adachi K., Ikari Y., Matsumoto K., Shimizu K., et al. Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine. J. Nucl. Med. 50 6 (2009) 887-892
112. Seneca N., Zoghbi S.S., Skinbjerg M., Liow J.S., Hong J., Sibley D.R., et al. Occupancy of dopamine D 2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA. Synapse 62 10 (2008) 756-763
113. Shearman L.P., Stribling D.S., Camacho R.E., Rosko K.M., Wang J., Tong S., et al. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents. Eur. J. Pharmacol. 579 1-3 (2008) 215-224
114. Skaddan M.B., Kilbourn M.R., Snyder S.E., and Sherman P.S. Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors. J. Cereb. Blood Flow Metab. 21 2 (2001) 144-148
115. Sovago J., Farde L., Halldin C., Schukin E., Schou M., Laszlovszky I., et al. Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756. Brain Res. Bull. 67 3 (2005) 219-224
116. Stahle L., and Borg N. Transport of alovudine (3′-fluorothymidine) into the brain and the cerebrospinal fluid of the rat, studied by microdialysis. Life Sci. 66 19 (2000) 1805-1816
117. Stain F., Barjavel M.J., Sandouk P., Plotkine M., Scherrmann J.M., and Bhargava H.N. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-d-glucuronide in the rat. J. Pharmacol. Exp. Ther. 274 2 (1995) 852-857
118. Sumiyoshi T., Kido H., Sakamoto H., Urasaki K., Suzuki K., Yamaguchi N., et al. Time course of dopamine1,2 and serotonin2 receptor binding of antipsychotics in vivo. Pharmacol. Biochem. Behav. 49 1 (1994) 165-169
119. Suzuki G., Kawagoe-Takaki H., Inoue T., Kimura T., Hikichi H., Murai T., et al. Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists. J. Pharmacol. Sci. 110 3 (2009) 315-325
120. Taber M.T., Wright R.N., Molski T.F., Clarke W.J., Brassil P.J., Denhart D.J., et al. Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. Pharmacol. Biochem. Behav. 80 3 (2005) 521-528
121. Takano A., Suhara T., Kusumi I., Takahashi Y., Asai Y., Yasuno F., et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 1 (2006) 75-81
122. Terry G.E., Liow J.S., Zoghbi S.S., Hirvonen J., Farris A.G., Lerner A., et al. Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage 48 2 (2009) 362-370
123. Tokunaga Y., Nakashima M., Sasaki H., Tomiyama N., Nakashima M.N., Ichikawa M., et al. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study. Biol. Pharm. Bull. 23 12 (2000) 1491-1496
124. Tsai T.H. Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis. Br. J. Pharmacol. 132 6 (2001) 1310-1316
125. Tsai T.H., and Chen C.F. Measurement and pharmacokinetic analysis of buspirone by means of brain microdialysis coupled to high-performance liquid chromatography with electrochemical detection. J. Chromatogr. A 762 1-2 (1997) 269-273
126. Tsai T.H., and Chen Y.F. Simultaneous determination of cefazolin in rat blood and brain by microdialysis and microbore liquid chromatography. Biomed. Chromatogr. 14 4 (2000) 274-278
127. Tsai T.H., and Chen Y.F. Pharmacokinetics of metronidazole in rat blood, brain and bile studied by microdialysis coupled to microbore liquid chromatography. J. Chromatogr. A 987 1-2 (2003) 277-282
128. Tsai T.H., and Liang C. Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis. Int. J. Pharm. 216 1-2 (2001) 61-66
129. Tsai T.H., and Liu M.C. Determination of unbound theophylline in rat blood and brain by microdialysis and liquid chromatography. J. Chromatogr. A 1032 1-2 (2004) 97-101
130. Tsai T.H., Chen Y.F., Chou C.J., and Chen C.F. Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection. J. Chromatogr. A 870 1-2 (2000) 221-226
131. Tong X., and Patsalos P.N. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br. J. Pharmacol. 133 6 (2001) 867-874
132. Tong X., Ratnaraj N., and Patsalos P.N. Vigabatrin extracellular pharmacokinetics and concurrent gamma-aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis. Epilepsia 50 2 (2009) 174-183
133. Umbrain V.J., Lauwers M.H., Shi L., Smolders I., Michotte Y., and Poelaert J. Comparison of the effects of intrathecal administration of levobupivacaine and lidocaine on the prostaglandin E2 and glutamate increases in cerebrospinal fluid: a microdialysis study in freely moving rats. Br. J. Anaesth. 102 4 (2009) 540-545
134. Urayama A., Yamada S., Hirano K., Deguchi Y., and Kimura R. Brain receptor binding characteristics and pharmacokinetic-pharmacodynamic analysis of thyrotropin-releasing hormone analogues. Life Sci. 70 6 (2001) 647-657
135. uther-Conrad W., Fischer S., Hiller A., Nielsen E.O., Timmermann D.B., Steinbach J., et al. Molecular imaging of alpha7 nicotinic acetylcholine receptors: design and evaluation of the potent radioligand [18F]NS10743. Eur. J. Nucl. Med. Mol. Imaging 36 5 (2009) 791-800
136. Van L.K., Bormans G., Sanabria-Bohorquez S.M., de G.T., Dupont P., De I L., et al. In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist. Biol. Psychiatry 64 2 (2008) 153-161
137. Vastag M., and Keseru G.M. Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Curr. Opin. Drug Discov. Devel. 12 1 (2009) 115-124
138. Venkatakrishnan K., Tseng E., Nelson F.R., Rollema H., French J.L., Kaplan I.V., et al. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab. Dispos. 35 8 (2007) 1341-1349
139. Verbeeck R.K. Blood microdialysis in pharmacokinetic and drug metabolism studies. Adv. Drug Deliv. Rev. 45 2-3 (2000) 217-228
140. Videbaek C., Toska K., Friberg L., Holm S., Angelo H.R., and Knudsen G.M. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. J. Cereb. Blood Flow Metab. 21 1 (2001) 92-97
141. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301 11 (2009) 1148-1154
142. Walker M.C., Alavijeh M.S., Shorvon S.D., and Patsalos P.N. Microdialysis study of the neuropharmacokinetics of phenytoin in rat hippocampus and frontal cortex. Epilepsia 37 5 (1996) 421-427
143. Walker M.C., Tong X., Perry H., Alavijeh M.S., and Patsalos P.N. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br. J. Pharmacol. 130 2 (2000) 242-248
144. Wang X., Ratnaraj N., and Patsalos P.N. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 13 8 (2004) 574-581
145. Waterhouse R.N., Chang R.C., Atuehene N., and Collier T.L. In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. Synapse 61 7 (2007) 540-546
146. Watson J., Wright S., Lucas A., Clarke K.L., Viggers J., Cheetham S., et al. Receptor occupancy and brain free fraction. Drug Metab. Dispos. 37 4 (2009) 753-760
147. Wu Y.T., Tsai T.R., Lin L.C., and Tsai T.H. Liquid chromatographic method with amperometric detection to determine acteoside in rat blood and brain microdialysates and its application to pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853 1-2 (2007) 281-286
148. Wu Y.T., Lin L.C., and Tsai T.H. Measurement of free hydroxytyrosol in microdialysates from blood and brain of anesthetized rats by liquid chromatography with fluorescence detection. J. Chromatogr. A 1216 16 (2009) 3501-3507
149. Xie R., Hammarlund-Udenaes M., de Boer A.G., and de Lange E.C. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol. 128 3 (1999) 563-568
150. Zhang W., and Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 141 3 (1999) 267-278